smwllgarcia01

healthcare

No image available
Not reviewed
Contact information
Sorafenib is an active ingredient in the original anticancer drug Nexavar. Included in the group of protein kinase inhibitors. Sorafenib inhibits the development of tumor cells. The drug was first released in Germany by the pharmaceutical company Bayer AG. The pills were expensive and out of reach for most patients with tumors. 

Contact information

smwllgarcia01
1973 West Fork Drive
, FL 33324 Plantation
United States of America
Directions

Contact person
Smwll Garcia

Callback request Write a message
Submit a review
Tell a friend

Your message to smwllgarcia01

Please complete the field highlighted in red.
Please complete the field highlighted in red.
Invalid email address
* required fields
Invalid characters. Only numbers and space characters are possible.

I accept the privacy policy.

Profile active since 04/12/2021  |  Last update: 04/12/2021   |  Report profile

More transparency and security while looking for competent professionals

Authentic customer opinions
Take advantage of other customers' experiences: ProvenExpert's authenticated customer reviews can help you choose the right product or service.
Effective customer feedback
ProvenExpert allows the entire service spectrum of a company (e.g. customer service, consulting) to be reviewed. This way you get a detailed overview of your service quality in all areas.
Independent reviews
ProvenExpert is free, independent, ad-free, and neutral. Customers make reviews of their own accord — their opinions are not for sale. And the content of reviews cannot be influenced by money or by any other means.

A good reputation is the world's
best form of advertising!

85% of all consumers trust online reviews just as much as they do personal recommendations.

Let ProvenExpert give your business a boost with the best advertising in the world: the opinions of satisfied customers.
Review Guidelines  |  Quality Assurance  |  Privacy Policy  |  Legal Notice  © 2011 - 2021 Expert Systems GmbH
By using our website you agree to the use of cookies. Learn moreOK